BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026. "With the share ...

BAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth and double-digit operating income growth put us fully on track to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Organic revenue growth of 7% was supported by all operating segments. The overall phasing of earnings in the first half of the year developed in line with our plan ...

Core Insights - Fresenius Medical Care (FME) emphasizes data-driven insights and real-world evidence to enhance patient care and improve outcomes for individuals with kidney disease globally [1][2] - The company presents 52 abstracts at the 62nd Congress of the European Renal Association (ERA), focusing on critical areas of nephrology, including home care, critical care, and hemodiafiltration [2][4] Research Highlights - Key presentations include studies on intradialytic arterial oxygen saturation instability, health status in hemodiafiltration versus hemodialysis, and the impact of fluid overload on hospitalization risk [4][5] - The CONVINCE trial analysis links hemodiafiltration to slower health decline and improved quality of life in dialysis patients [4][5] Innovations and Collaborations - FME introduces a novel AI-based recipe recommendation system for dialysis patients, enhancing nutritional management [5] - The company aims to optimize treatment durations in hemodialysis to improve survival outcomes, reinforcing treatment time as a modifiable factor [5] Company Overview - Fresenius Medical Care serves approximately 4.2 million patients worldwide, with around 299,000 patients receiving dialysis treatments through its network of 3,675 clinics [4][6] - The company is a leading provider of dialysis products and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [6]